financetom
Business
financetom
/
Business
/
Schlumberger, ChampionX $7.8 Billion Planned Merger May 'Substantially' Reduce Competition in UK Energy Market
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Schlumberger, ChampionX $7.8 Billion Planned Merger May 'Substantially' Reduce Competition in UK Energy Market
Mar 27, 2025 6:07 AM

08:50 AM EDT, 03/27/2025 (MT Newswires) -- Schlumberger ( SLB ) and ChampionX's ( CHX ) $7.8 billion planned merger could "substantially" reduce competition in the UK energy market, the country's Competition and Markets Authority said Thursday in an update about the phase one investigation into the potential deal.

"The CMA has decided, on the evidence currently available to it, that it is or may be the case that this merger may be expected to result in a substantial lessening of competition within a market or markets in the United Kingdom," the CMA said.

Schlumberger ( SLB ) and ChampionX ( CHX ) said in April 2024 that Schlumberger ( SLB ) will acquire ChampionX ( CHX ) in an all-stock transaction.

The regulator, which launched its inquiry on Jan. 29, said Thursday it will refer the merger for an in-depth phase 2 investigation unless the parties propose undertakings to potentially mitigate the competition issues raised in its phase 1 decision by April 3.

Schlumberger ( SLB ) and ChampionX ( CHX ) did not immediately respond to requests for comment from MT Newswires.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Sarepta Therapeutics Q4 Non-GAAP Earnings, Revenue Rise
Sarepta Therapeutics Q4 Non-GAAP Earnings, Revenue Rise
Feb 26, 2025
04:48 PM EST, 02/26/2025 (MT Newswires) -- Sarepta Therapeutics ( SRPT ) reported Q4 non-GAAP net earnings late Wednesday of $1.90 per diluted share, up from $0.82 a year earlier. Analysts polled by FactSet expected $2.00. Total revenue for the quarter ended Dec. 31 was $658.4 million, up from $396.8 million a year earlier. Analysts surveyed by FactSet expected $636.1...
Universal Health Services Q4 Adjusted Earnings, Revenue Increase -- Shares Rise After Hours
Universal Health Services Q4 Adjusted Earnings, Revenue Increase -- Shares Rise After Hours
Feb 26, 2025
04:48 PM EST, 02/26/2025 (MT Newswires) -- Universal Health Services ( UHS ) reported Q4 adjusted earnings late Wednesday of $4.92 per diluted share, up from $3.13 a year earlier. Analysts polled by FactSet expected $4.14. Net revenue for the quarter ended Dec. 31 was $4.11 billion, up from $3.70 billion a year earlier. Analysts surveyed by FactSet expected $4.01...
Chemed Q4 Adjusted Earnings, Revenue Rise; 2025 Outlook Set
Chemed Q4 Adjusted Earnings, Revenue Rise; 2025 Outlook Set
Feb 26, 2025
04:49 PM EST, 02/26/2025 (MT Newswires) -- Chemed ( CHE ) reported Q4 adjusted earnings late Wednesday of $6.83 per diluted share, up from $6.60 a year earlier. Three analysts surveyed by FactSet expected $6.78. Revenue for the quarter ended Dec. 31 was $640 million, up from $585.9 million a year earlier. Three analysts polled by FactSet expected $636.1 million....
Revolution Medicines Q4 Net Loss Narrows
Revolution Medicines Q4 Net Loss Narrows
Feb 26, 2025
04:51 PM EST, 02/26/2025 (MT Newswires) -- Revolution Medicines ( RVMD ) reported a Q4 net loss late Wednesday of $1.12 per diluted share, narrowing from a loss of $1.14 a year earlier. Analysts polled by FactSet expected a loss of $1.02 The company did not report any revenue for the quarter ended Dec. 31. The company expects its current...
Copyright 2023-2026 - www.financetom.com All Rights Reserved